- Policy
- Why Galvusmet is priced same as salt-modified and generics
- by Lee, Tak-Sun Apr 13, 2022 06:03am
- Prices of DPP-4 inhibitor Galvus (vildagliptin) and Galvusmet (vildagliptin+metformin) latecomers show that the original Galvus’s price is still set high, but the price of the original Galvusmet (50/500mg) is set at the same level as its salt-modified and generic versions. Also, Galvus’s price had fallen 30% with premium pricing after t
- Company
- “NOAC Eliquis is safe for use in high-risk groups”
- by Apr 13, 2022 06:02am
- The bleeding safety of the novel oral anticoagulant (NOAC) ‘Eliquis (apixaban)’ was reaffirmed through clinical practice guidelines of major academic societies. On the 12th, BMS Korea and Pfizer Korea announced that they have hosted a ‘VMC Master of Masters Webinar’ on the 11th to share the latest advances in preventive therapies for
- Policy
- Korea loses $9 billion a year in exports
- by Lee, Jeong-Hwan Apr 13, 2022 06:02am
- If low- and mid-income countries such as Africa and Central America fail to raise their collective immunity levels sufficiently, it will have a negative impact on the economy, such as a decrease in export profits of high-income countries. This is because countries around the world are linked to each other by trade and investment, and the country
- Company
- Propecia is sold in a new package
- by Apr 13, 2022 06:02am
- Organon Korea announced on the 11th that it will introduce a new package of the oral male hair loss treatment Propecia (Finasteride). As for the new package, it applied CI of Organon Korea company. Propecia, which has been sold by MSD Korea for more than 20 years since its launch in Korea in 2000, was officially launched and relocated by Orga
- Policy
- Galvusmet latecomers face a price war since launch
- by Lee, Tak-Sun Apr 12, 2022 06:05am
- How price will affect sales of the DPP-4i antidiabetic treatment Galvusmet’s latecomers is gaining attention. Hanmi Pharmaceutical, which had been the first to release a drug to the market, had opted to set its price lower than planned, and the price of the original Galvusmet had also fallen due to the introduction of generics. The price
- Company
- KRPIA BOD meets Oh Chang-hyun, the new head
- by Eo, Yun-Ho Apr 12, 2022 06:05am
- KRPIA BOD will hold its first face-to-face meeting with Oh Chang-hyun, director of the MOHW's insurance pharmaceutical dept. According to related industries, KRPIA Board of Director (BOD) will hold a meeting with Oh Chang-hyun, the new manager, and members of the MOHW's Insurance and Pharmaceutical Affairs on the 15th. The meeting is expec
- Company
- No. of employees decline sharply due to restructuring/reorgs
- by Apr 12, 2022 06:04am
- The number of employees at multinational pharmaceutical companies has declined sharply due to their active restructuring and reorganizations. Over 200 employees have been laid off in just 4 companies - Roche Korea, Lilly Korea, Sanofi-Aventis Korea, and Zuellig Pharma Korea. According to the Financial Supervisory Service, the number of em
- Company
- Lutathera’s partner ‘LysaKare’ may be prescribed at GHs
- by Eo, Yun-Ho Apr 11, 2022 05:58am
- ‘LysaKare’, the drug concomitantly used with the neuroendocrine tumor treatment ‘Latathera’ may soon be prescribed at general hospitals. According to industry sources, Novartis Korea’s ‘LysaKare (L-arginine hcl/L-lysine hcl) has passed the drug committee (DC) reviews at 3 of the Big 5 general hospitals &8211; Samsung Medical Center
- Policy
- The adverse drug reaction rate of Trulicity is 19%
- by Lee, Hye-Kyung Apr 11, 2022 05:58am
- As a result of a six-year post-marketing survey of Type 2 diabetes treatment Trulicity in Lilly Korea, 15 cases of serious adverse drug reactions that cannot be excluded from causal relationships were reported. The permit will be changed as 62 unexpected adverse drug reactions, which cannot exclude causal relationships, also occurred. The
- Policy
- NHIS to study measures on improving the PVA system
- by Lee, Tak-Sun Apr 11, 2022 05:58am
- With a study on improving the price-volume agreement (PVA) system in plan, the possibility that the improvement may increase drugs subject to PVA is being raised. According to industry sources on the 8th, the National Health Insurance Service is preparing to conduct a research to ‘evaluate the performance of and improve the Price-Volume
